Rahuman Salim

Liverpool, ENG, GB 
Liverpool, ENG, GB 
OverviewLocationsClinical Research

Overview

Rahuman Salim practices in Liverpool, United Kingdom. Their top areas of expertise are Shwachman-Diamond Syndrome, Myelodysplastic Syndrome (MDS), Aplastic Anemia, Acute Myeloid Leukemia (AML), and Bone Marrow Transplant.

Their clinical research consists of co-authoring 9 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

Liverpool, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A UK Multicentre Study of Haploidentical Stem Cell Transplantation in Patients With Haematological Malignancies
A UK Multicentre Study of Haploidentical Stem Cell Transplantation in Patients With Haematological Malignancies
Enrollment Status: Completed
Publish Date: May 03, 2024
Intervention Type: Procedure
Study Phase: Phase 2
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
Enrollment Status: Completed
Publish Date: March 03, 2023
Intervention Type: Drug, Other
Study Phase: Phase 3
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
Enrollment Status: Terminated
Publish Date: September 26, 2022
Intervention Type: Drug
Study Drug: Rigosertib
Study Phase: Phase 3
View 2 Less Clinical Trials

9 Total Publications

Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML/MDS.
Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML/MDS.
Journal: Blood advances
Published: December 06, 2022

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Salim's expertise for a condition
ConditionClose
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile